NEW YORK — Actinium Pharmaceuticals appointed Dr. Ajit Shetty to its board of directors. Dr. Shetty is a pharmaceutical industry executive with 36 years of experience at Johnson & Johnson and its subsidiary Janssen. Most recently Dr. Shetty served as the Head of Enterprise Supply Chain at J&J where he was responsible for the transformation and optimization of J&J’s global supply chain.
“Dr. Shetty is a highly accomplished pharmaceutical executive with a demonstrated ability to lead and manage growth on a global basis with expertise in supply chain and commercialization activities,” said Sandesh Seth, executive chairman of Actinium. “His plethora of experiences, wealth of knowledge and relationships gained in his 36 years at Johnson & Johnson will be invaluable to Actinium as we execute on the development of our clinical programs. I welcome Dr. Shetty to the Actinium Board and I look forward to working with him and the Actinium team in building an innovative company focused on improving patient outcomes with our novel radioimmunotherapies.”
Dr. Shetty said, “Actinium is developing therapies that have the potential to dramatically improve patient outcomes and to transform important areas of medicine such as bone marrow transplant. I am honored and excited to join the Actinium board of directors and look forward to working with the Actinium Board, executive management and the team to drive value for all Actinium stakeholders.”
Dr. Shetty joined Janssen Pharmaceutica in 1976 ultimately rising to the position of president in 1986 where he led the establishment of Janssen’s business in the United States. From 1999 to 2008, he was managing director of Janssen Pharmaceutica, during this time the Janssen Group of companies’ global sales grew from $1 billion to $8 billion, and from 2004 until 2012 he was chairman of the board. In Dr. Shetty’s most recent role at Johnson & Johnson he was head of Enterprise Supply Chain, where he reported to the CEO and was responsible for the transformation and optimization of Johnson & Johnson’s supply chain. Dr. Shetty earned a Ph.D. in Metallurgy and B.A. Natural Sciences from Trinity College, Cambridge University and a Master of Business Administration from Carnegie Mellon University.
“Actinium is developing therapies that have the potential to dramatically improve patient outcomes and to transform important areas of medicine such as bone marrow transplant. I am honored and excited to join the Actinium board of directors and look forward to working with the Actinium board, executive management and the team to drive value for all Actinium stakeholders,” said Dr. Shetty.
Actinium Pharmaceuticals is a biopharmaceutical company developing targeted therapies for patients with cancers lacking effective treatment options.